Business
CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product candidate developed on its proprietary THANK-u Plus™ platform for relapsed/refractory multiple myeloma (R/R MM), and for CT1190B, an allogeneic CD19/CD20-targeting CAR-T product candidate for relapsed/refractory non-Hodgkin's lymphoma (R/R NHL). The data showed that both allogeneic CAR-T produc
About this update from Carsgen Therapeutics Holdings Ltd.
[{"type":"text","content":"SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product candidate developed on its proprietary THANK-u Plus™ platform for relapsed/refractory multiple myeloma (R/R MM), and for CT1190B, an allogeneic CD19/CD20-targeting CAR-T product candidate for relapsed/refractory non-Hodgkin's lymphoma (R/R NHL). The data showed that both allogeneic CAR-T products demonstrated initially favorable safety profiles and encouraging efficacy signals.","length":628,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/科济药业)","displaySize":"","headline":null,"caption":"(PRNewsfoto/科济药业)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/5526ae7fcec6d3697a745ab2d0333d4b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pxBnvmJ9CDgFxmtruRHsdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/5526ae7fcec6d3697a745ab2d0333d4b","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/1722549/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Data for CT0596 in Relapsed/Refractory Multiple Myeloma","length":55,"tagName":"p"},{"type":"text","content":"CT0596 is a BCMA-targeted allogeneic CAR-T cell therapy candidate developed based on CARsgen's THANK-u Plus™ platform and is currently being evaluated in an investigator-initiated trial (IIT) for malignant plasma cell neoplasms. The study has now entered the dose expansion phase with a determined lymphodepletion regimen. Future work will involve dose escalation of the cells to further determine the Recommended Dose (RD).","length":428,"tagName":"p"},{"type":"text","content":"As of June 24, 2025, the reported clinical trial (NCT06718270) had enrolled 8 R/R MM patients who received CT0596 infusion from the dose-escalation phase. The median number of prior lines of therapy was 4.5 (range: 3-9). Five patients had prior exposure to triple-class drugs (PI, IMiD, and anti-CD38 monoclonal antibody), and five patients had a history of autologous stem cell transplantation. CAR-T cell doses administered were 1.5e8 (n=1), 3e8 (n=5...